Replies to post #9621 on Lexington Biosciences Inc. (LXGTF)

[StockBro75]

I think its specifically Cardiovascular devices that have an average of 6 months of testing before FDA clearance in the 510K accelerated path to market program. But since some cardiovascular devices are invasive, and LXGTF HeartSentry is not invasive at all, and since the early testing showed such strong correlation to the predicate ultrasound tech, it seems reasonable to assume it will have a faster than average path through clinical tests.